Datafin

Data-driven stock analysis platform for global investors.

Sitemap
HomeScreenerValuationSector Analysis
Resources
LibraryDatafin GuideMetric MethodologyValuation MethodologiesFAQPricingWho Is Datafin?Communication
Legal
Privacy PolicyTerms of UseCookie PolicyKVKK NoticeRefund Policy
Data Sources

Financial data sourced from official regulatory filings and verified market data providers. Metrics calculated using GAAP/IFRS standards.

Disclaimer

The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

Investment decisions involve risk. Verify data independently and consult a licensed advisor when needed.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved.

Last updated: April 2026

HIK FINANCIAL STATEMENTS

Hikma Pharmaceuticals PLC — balance sheet, income statement and cash flow trends

HIKHikma Pharmaceuticals PLC

🇬🇧 UK · LSE · Healthcare · Drug Manufacturers - Specialty & Generic

Value itDuel
PriceFinancialsPeers

Income Statement

Quarterly progression — trailing-twelve-month values
RevenueNet Income
01 B2 B3 B202020212022202320242025

Profit Funnel

Q2 2025 · TTM
Revenue3.4 B $Gross Profit1.4 B $ · 41%Operating Income564.5 M $ · 17%Pre-tax Income520.1 M $ · 15%Net Income402.8 M $ · 12%

Percentages are relative to revenue.

Key Figures

YoY change
Revenue3.4 B $+16.8%
Gross Profit1.4 B $-1.3%
Operating Income564.5 M $-8.8%
EBITDA670 M $-15.3%
Net Income402.8 M $+112.0%

Peer Comparison· Drug Manufacturers - Specialty & Generic

CompanyRev. GrowthGross MarginEBITDA MarginNet Margin
HIK7.4%41.4%20.0%12.0%
TRILC32.0%33.8%28.5%-2.2%
ASRT-14.2%44.3%-5.7%-34.9%
ANIK23.2%58.6%-4.0%-9.5%
BTAI-63.3%27.8%-8,509.3%-11,078.5%
SIGA-22.1%65.4%29.3%21.6%
Industry median7.5%60.6%18.2%4.0%
CompanyRev. GrowthGross MarginEBITDA MarginNet Margin
HIK7.4%41.4%20.0%12.0%
HLN-26.7%61.5%25.2%12.6%
Industry median7.5%60.6%18.2%4.0%

Balance Sheet

Quarterly period-end values
Total AssetsTotal LiabilitiesEquity
02 B4 B202020212022202320242025

Capital Structure

Q2 2025
Total Assets5.7 B
  • Equity2.6 B $46%
  • Current Liabilities1.5 B $26%
  • Long-term Liabilities1.6 B $28%

Key Figures

YoY change
Total Assets5.7 B $+21.2%
Total Liabilities3.1 B $+24.1%
Total Equity2.6 B $+18.0%
Cash & ST Investments354.1 M $+72.7%
Total Debt1.6 B $+34.7%
Net Debt1.3 B $+29.4%

Peer Comparison· Drug Manufacturers - Specialty & Generic

CompanyCurrent RatioDebt/EquityNetDebt/EBITDAEquity/Assets
HIK1.8261.8%1.8745.7%
TRILC0.99207.6%2.7123.5%
ASRT1.8253.3%5.3935.8%
ANIK4.4619.2%3.3074.6%
BTAI0.62-95.0%-1.44-310.2%
SIGA3.250.4%-5.2769.1%
Industry median2.2246.3%1.2445.7%
CompanyCurrent RatioDebt/EquityNetDebt/EBITDAEquity/Assets
HIK1.8261.8%1.8745.7%
HLN0.9252.3%3.5050.3%
Industry median2.2246.3%1.2445.7%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values
Operating Cash FlowCapital ExpendituresFree Cash Flow
0200 M400 M600 M202020212022202320242025

Cash Flow Bridge

Q2 2025 · TTM
0200 M400 M389.9 M $Operating-384.7 M $Investing16.2 M $Financing21.5 M $Net Change

Key Figures

YoY change
Operating Cash Flow389.9 M $-35.9%
Capital Expenditures195.4 M $+15.6%
Free Cash Flow194.6 M $-55.7%
Dividends Paid-181.9 M $-232.8%

Peer Comparison· Drug Manufacturers - Specialty & Generic

CompanyCF MarginFCF MarginCapEx RatioCF/Net Income
HIK11.6%5.8%5.8%96.8%
TRILC10.9%-0.3%11.2%-505.5%
ASRT-6.9%-6.9%0.0%19.8%
ANIK5.6%0.9%4.7%-58.5%
BTAI-8,438.4%-8,438.4%0.0%76.2%
SIGA29.6%29.2%0.4%136.9%
Industry median15.2%11.6%2.5%84.3%
CompanyCF MarginFCF MarginCapEx RatioCF/Net Income
HIK11.6%5.8%5.8%96.8%
HLN12.5%11.3%1.2%99.0%
Industry median15.2%11.6%2.5%84.3%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on HIK

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 7, 26. This content is for informational purposes only and is not investment advice.